DE60204722D1 - Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten - Google Patents

Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten

Info

Publication number
DE60204722D1
DE60204722D1 DE60204722T DE60204722T DE60204722D1 DE 60204722 D1 DE60204722 D1 DE 60204722D1 DE 60204722 T DE60204722 T DE 60204722T DE 60204722 T DE60204722 T DE 60204722T DE 60204722 D1 DE60204722 D1 DE 60204722D1
Authority
DE
Germany
Prior art keywords
sub
treatment
mediated diseases
cell
quinazoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60204722T
Other languages
English (en)
Other versions
DE60204722T2 (de
Inventor
Corine Moore
Keith Oldham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60204722D1 publication Critical patent/DE60204722D1/de
Publication of DE60204722T2 publication Critical patent/DE60204722T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60204722T 2001-11-23 2002-11-20 Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten Expired - Lifetime DE60204722T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0128108.8A GB0128108D0 (en) 2001-11-23 2001-11-23 Therapeutic use
GB0128108 2001-11-23
PCT/GB2002/005222 WO2003045395A1 (en) 2001-11-23 2002-11-20 Quinazoline derivatives for the treatment of t cell mediated diseases

Publications (2)

Publication Number Publication Date
DE60204722D1 true DE60204722D1 (de) 2005-07-21
DE60204722T2 DE60204722T2 (de) 2006-05-11

Family

ID=9926329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60204722T Expired - Lifetime DE60204722T2 (de) 2001-11-23 2002-11-20 Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten

Country Status (7)

Country Link
US (1) US7160891B2 (de)
EP (1) EP1450808B8 (de)
AT (1) ATE297733T1 (de)
AU (1) AU2002343047A1 (de)
DE (1) DE60204722T2 (de)
GB (1) GB0128108D0 (de)
WO (1) WO2003045395A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112969A (pt) 2000-08-04 2004-06-22 Dmi Biosciences Inc Método de utilização de dicetopiperazinas e composições contendo-as
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
AU2002250394A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (de) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Modulatoren von rezeptor-typ-kinase und anwendungsverfahren
KR20120091266A (ko) 2003-05-15 2012-08-17 디엠아이 바이오사이언시스, 인크 T-세포 매개성 질환의 치료 방법
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
KR20060100388A (ko) * 2003-09-25 2006-09-20 아스트라제네카 아베 퀴나졸린 유도체
ATE532782T1 (de) 2003-09-26 2011-11-15 Exelixis Inc C-met-modulatoren und anwendungsverfahren
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
CN1972688B (zh) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
EP1833482A4 (de) 2005-01-03 2011-02-16 Myriad Genetics Inc Verbindungen und ihre therapeutische verwendung
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20090221644A1 (en) * 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
US7869850B2 (en) * 2005-09-29 2011-01-11 Nellcor Puritan Bennett Llc Medical sensor for reducing motion artifacts and technique for using the same
US8073518B2 (en) 2006-05-02 2011-12-06 Nellcor Puritan Bennett Llc Clip-style medical sensor and technique for using the same
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
CN102088979B (zh) 2008-05-13 2013-10-16 阿斯利康(瑞典)有限公司 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-{[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]氧基}喹唑啉的富马酸盐
EP2300011A4 (de) 2008-05-27 2012-06-20 Dmi Life Sciences Inc Therapeutische verfahren und verbindungen
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EA019959B1 (ru) 2009-01-16 2014-07-30 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
CN102068434B (zh) * 2011-01-25 2012-08-22 林治华 4-(环己基)-胺基喹唑啉类化合物的应用
BR112014007657A2 (pt) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação
JP6203734B2 (ja) 2011-10-10 2017-09-27 アンピオ ファーマシューティカルズ,インコーポレイテッド 変形性関節疾患の治療
EA201490737A1 (ru) 2011-10-28 2014-09-30 Ампио Фармасьютикалз, Инк. Лечение ринита
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
RU2020136589A (ru) 2014-08-18 2020-12-24 Ампио Фармасьютикалз, Инк. Лечение дегенеративных заболеваний суставов
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN107814793A (zh) * 2017-12-30 2018-03-20 胡张艳 一种小分子Src酪氨酸激酶抑制剂塞卡替尼及其中间体的制备方法
CN107987064A (zh) * 2017-12-30 2018-05-04 王兆举 一种治疗骨癌的药物塞卡替尼的制备方法
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚(上海)生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN110357858B (zh) 2018-04-09 2022-02-18 威尚(上海)生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN108395410A (zh) * 2018-05-09 2018-08-14 日照市普达医药科技有限公司 一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
CN114605273B (zh) * 2022-03-29 2023-06-02 南昌航空大学 一种钯催化co参与的1,4-烯炔芳构化反应合成芳胺基酚类化合物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2378291A1 (en) * 1999-07-07 2001-01-18 Astrazeneca Uk Limited Quinazoline derivatives
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція

Also Published As

Publication number Publication date
EP1450808A1 (de) 2004-09-01
GB0128108D0 (en) 2002-01-16
US7160891B2 (en) 2007-01-09
EP1450808B8 (de) 2006-01-04
WO2003045395A1 (en) 2003-06-05
AU2002343047A1 (en) 2003-06-10
US20050038050A1 (en) 2005-02-17
DE60204722T2 (de) 2006-05-11
EP1450808B1 (de) 2005-06-15
ATE297733T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
ATE297733T1 (de) Quinazolinderivate für die behandlung durch t- zellen vermittelter krankheiten
DE60319066D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
GB0226931D0 (en) Chemical compounds
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
GB0209891D0 (en) Novel compounds
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ATE495187T1 (de) Dalda-analoge und ihre verwendung
BR9809185A (pt) Diidropiranos fundidos
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
NO20044549L (no) Bisykliske 6-alkaliden-penemer som beta-laktamaseinhibitorer
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
ATE352295T1 (de) Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
WO2002074735A3 (de) Biurethanderivate
UY27587A1 (es) Heterociclos terapéuticos
DE50203154D1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
DE60315597D1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
DE60224805D1 (de) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition